Floatz logo

Rifaximin

Nonalcoholic Steatohepatitis

Imperial College LondonSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

131 Active assets in the Nonalcoholic Steatohepatitis cohort.

Asset / SponsorPhaseRating
Resmetirom
City University of New York
Phase 4BBB
Pentoxifylline
Al-Azhar University
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB
Semaglutide
Cascade Pharmaceuticals, Inc
Phase 4BBB
Firsocostat
Gilead Sciences
Phase 2BBB

View all 50 →

Same molecule, other indications

Rifaximin is also rated in:

hepatic encephalopathyDormant
BBB
Indicative ·
75 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →
AscitesDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →